VivoSeq
Nephrology

Nephropathy

106

Pipeline Programs↗

17

Active Trials↗

45

Companies Involved↗

Nephropathy is a highly competitive landscape with 106 programs across 45 companies. The most active players are Takeda, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Rigel Pharmaceuticals. 32 therapies are approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

11/100

Mech. Concentration

10/100

Completion Rate

79/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Phase 1R

Rigel Pharmaceuticals

1 program

Phase 2K

Keymed Biosciences Co.Ltd

1 program

Phase 2N

NovelMed Therapeutics

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical17

Finerenone

Bayer

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Sirolimus

Prism Pharmaceuticals

Daratumumab

Johnson & Johnson

Pentoxifylline

Validus Pharmaceuticals

Phase 16

Dapagliflozin

AstraZeneca

Mezagitamab

Takeda

BQ-123

Medical University of Vienna

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Anti-CD19 CAR NK Cells

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 226

Belimumab

Glaxo Dba Glaxosmithkline

Avacopan

Amgen

Methylprednisolone

Pfizer

Cyclophosphamide

Baxter Healthcare Corporation

Prednisone

Roxane Laboratories

Phase 325

Iloprost

BTG International Inc.

Epoetin Beta

Roche

L-Carnitine

Iperboreal Pharma Srl

N-Acetylcysteine

Novartis

Ramipril

Viking Therapeutics, Inc.

Approved32

Rituximab

Roche

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Losartan

Organon and Co

Sodium Bicarbonate

Abbott

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

90%

Small molecule

114 of 127 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody97%Cell therapy22%Protein / enzyme1<1%RNA therapy1<1%

Small molecule leads; the ring shows all 127 classified programs, each share of the total. Modality classified for 100% of 132 pipeline programs.

Analysis

Trial Status

139

clinical trials

Completed73 · 53%
Unknown status30 · 22%
Terminated13 · 9%
Recruiting9 · 6%
Withdrawn6 · 4%
Not yet recruiting4 · 3%
Other4 · 3%

Clinical Trials

Trial Activity

139 trials

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Recruiting·MMayo Clinic·Phase 2·NCT06676579·16 enrolled
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Recruiting·Otsuka logoOtsuka·Phase 2·NCT06740526·25 enrolled
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Recruiting·FFondazione Schena·Phase 4·NCT04662723·878 enrolled
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Recruiting·—·N/A·NCT07056595·30 enrolled
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Recruiting·Roche logoRoche·Phase 3·NCT05797610·428 enrolled
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Recruiting·—·N/A·NCT03512132·200 enrolled
Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
Recruiting·SSt. Petersburg State Pavlov Medical University·N/A·NCT07074951·240 enrolled
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT05775042·70 enrolled
An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor NK Cell Injections (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
Recruiting·CChanghai Hospital·Phase 1·NCT06469190·36 enrolled
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Active, not recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 3·NCT06564142·605 enrolled
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Active, not recruiting·Otsuka logoOtsuka·Phase 3·NCT05248646·530 enrolled
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Not yet recruiting·WWuhan Createrna Science and Technology Co., Ltd·Phase 2·NCT06687174·72 enrolled
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
Not yet recruiting·NNovelMed Therapeutics·Phase 2·NCT06454110·10 enrolled
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Not yet recruiting·—·Phase 2·NCT06350630·334 enrolled
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy
Not yet recruiting·—·Phase 2·NCT05810311·30 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)